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Abstract
Introduction. Testicular tumors are heterogeneous group of neoplasms divided mainly into two types: seminomas 
and non-seminomas. Nucleolin (NCL) and nucleophosmin (NPM) are abundant nucleolar proteins involved in 
many physiologic and pathologic processes including cancer. Their overexpression was found in many tumors 
but it was not studied in testicular cancer.
Material and methods. The study was performed on tissue microarrays of 19 seminomas, 21 embryonal carci-
nomas and 11 yolk sac tumors. The expression of NCL and NPM was detected with monoclonal antibodies and 
visualized with EnVision FLEX/HRP technique. Immunohistochemical reactions were measured with Aperio 
ImageScope Software and analyzed as means of percentages of all immunopositive cells in three groups of re-
action intensity, i.e. 3+, 2+, and 1+ as well as of H-score. 
Results. Seminomas showed higher expression of nucleolin indicated by higher H-score and higher percentage of 
positive cells than non-seminomas. The differences in subpopulations of NCL-positive cells were also found. Em-
bryonal carcinomas and yolk sac tumors showed lower expression of NCL than seminomas indicated by H-score. 
The percentage of NCL-positive cells did not differ between embryonal carcinomas and seminomas while there 
were significant differences in subpopulations of cells. The percentage of NCL-positive cells in yolk sac tumors 
was lower than in seminomas. The results show different heterogeneity of subpopulations of NCL-positive cells 
in embryonal carcinomas and yolk sac tumors compared to seminomas. The analysis of nucleolin expression in 
embryonal carcinomas and yolk sac tumors showed no differences between these two tumor types. No differences 
in nucleophosmin expression between seminomas and non-seminomas were found.
Conclusions. The differences in the expression of nucleolin between two groups of germ cell testicular tumors 
found in the current study indicate a new aspect of biology of these neoplasms and require further studies on the 
role of nucleolin in germ cell tumorigenesis. (Folia Histochemica et Cytobiologica 2019, Vol. 57, No. 3, 139–145)
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Introduction
Testicular tumors are the most common cancer in 
young men between puberty and forties in Europe 
and they account for 1–3% of all cancers in men. The 
incidence and death rate in Poland are among the 
highest in European countries [1]. Germ cell testic-
ular tumors are heterogeneous group of neoplasms 
and based on their diverse histology and biological 
behavior they can be divided into seminomas and 
non-seminomas. Median age of patients with sem-
inoma is 35 years and ones with non-seminomas is 
25 years [2]. Compared to non-seminomas, semino-
mas present relatively uniform histology with large 
cells containing regular nuclei with one or more nucle-
oli [3]. Non-seminomas is diverse group of neoplasms 
that among others include embryonal carcinoma and 
yolk sac tumors as a pure malignancies or elements of 
mixed germ cell tumors. Embryonal carcinomas vary 
in histologic presentation from sheets of primitive-ap-
pearing cells to glandular or papillary structures with 
highly pleomorphic atypical nuclei with many nucleoli 
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and frequent mitoses. Less common in adult men yolk 
sac tumors show numerous histologic patterns from 
solid through microcystic and glandular to classic one 
with Schiller-Duval bodies [3, 4]. The most common 
histologic and molecular precursor of seminomas and 
non-seminomas is germ cell neoplasia in situ (GC-
NIS), which arises from primordial germ cells that 
failed to differentiate into spermatogonia. One of the 
first events in neoplastic transformation of germ cells 
is an expression of Oct4. Different programming of 
GCNIS results in transformation to seminoma or to 
embryonal carcinoma that is a neoplastic counterpart 
of the human embryonal stem cell [5–7]. GCNIS ex-
press several stem cell related markers such as Oct4, 
NANOG, c-KIT, PLAP, TSPY [2, 6, 8]. Seminoma 
cells have limited capacity to differentiate while 
embryonal carcinoma cells can differentiate into 
embryonic somatic lines or extraembryonal and troph-
oblastic structures [8]. Both embryonal carcinoma 
cells and seminoma cells express Oct4 and NANOG. 
Difference between seminomas and non-seminomas 
include expression of Sox17, high hTERT expression 
and high telomerase activity in seminomas and Sox2 
expression in embryonal carcinomas [2, 9, 10].
Nucleolus seen within the nucleus in standard 
histologic staining with hematoxylin and eosin is 
a structure composed of three elements: fibrillar 
centers (FC), dense fibrillar components (DFC) and 
granular components (GC) and it is a site of ribosome 
biogenesis [11]. Nucleolin (NCL), highly conservative 
protein, is a three-domain structure involved in many 
processes such as nucleolus formation, transcription 
of rDNA, maturation of rRNA, ribosomal assembly 
and nucleocytoplasmic transport, regulation of apop-
tosis and cell differentiation [11–13]. NCL is involved 
in wide variety of pathologic processes including 
cancer (as a promotor or suppressor), inflammation, 
neurodegeneration [12]. This protein is mainly de-
tected in nucleolus but also in nucleoplasm outside 
nucleolus [11, 14], cytoplasm and cell membrane 
[12]. Nucleophosmin (NPM) is another abundant 
nucleolar protein with possible aberrant cytoplasmic 
localization. Similarly to NCL it shuttles between 
nucleolus and nucleoplasm. Both proteins function as 
chaperones and they interact with numerous protein 
partners including themselves [15]. NCL and NPM 
overexpression was found in many tumors [16, 17]; 
however, their expression in testicular tumors has yet 
not been analyzed.
Materials and methods
The study was approved by the Bioethical Commission of 
the Pomeranian Medical University in Szczecin, Poland 
(approval number KB-0012/267/09/18).
All cases of germ cell testicular tumors diagnosed in Depart-
ments of Pathology of the 1st and the 2nd Clinical Hospitals 
of Pomeranian Medical University, Szczecin, Poland and 
Multispecialty Hospital, Gorzów Wielkopolski, Poland 
between May 2004 and April 2018 were re-analyzed by 
one pathologist (MM) and representative slides and paraf-
fin-embedded tissue blocks were selected for constructing 
tissue microarrays (TMA). All tissue samples for routine 
pathologic diagnosis were formalin-fixed and paraffin em-
bedded. Two main tumor types were selected for further 
studies — pure seminomas and mixed germ cell tumors. Due 
to high heterogeneity of the latter ones, cases containing only 
embryonal carcinomas and yolk sac tumor elements were 
selected for the study. 19 cases of seminomas and 27 cases 
of mixed germ cell tumors (21 cases of embryonal carcinoma 
elements and 11 cases of yolk sac tumor elements) were 
included in the study. 
Immunohistochemistry. All immunohistochemical (IHC) 
studies were performed on tissue microarray (TMA) slides. 
During histological evaluation areas of interest were en-
circled on a glass slide and afterwards cores of tissue were 
taken from representative sites of original paraffin blocks 
and were inserted into recipient paraffin blocks. To ensure 
the representativeness of the material 3 cores were taken 
from each area of interest. Each TMA were cut into 3 µm-
-thick section, deparrafinized and antigens were retrieved 
for IHC reactions (PT Link, Dako, Glostrup, Denmark). 
Endogenous peroxidase was blocked with hydrogen perox-
ide and slides were incubated with primary antibody. Two 
mouse anti-human antibodies were used for detecting stud-
ied proteins — anti-nucleolin (monoclonal antibody; clone 
4E2; Abcam, plc., Cambridge, UK; 1:2000 dilution, 37°C for 
90 min) and anti-nucleophosmin (monoclonal antibody; 
clone FC82291; Abcam, plc.; 1:2500 dilution, 37°C for 
90 min). Antigens retrieval procedures were tested and an-
tibodies were titrated for optimal IHC reactions that were 
visualized with EnVision FLEX/HRP (Dako). Slides were 
counterstained with hematoxylin, dehydrated and sealed 
with coverslips. One section of each TMA was also stained 
with hematoxylin and eosin for microscopic control of cores 
quality. Slides were immediately scanned with ScanScope 
slide scanner (Aperio Technologies Inc., Vista, CA, USA) 
and the analyses of IHC reactions were performed with 
Aperio ImageScope software (Aperio Technologies Inc.) 
(Fig. 1). Each evaluated area was selected manually to 
avoid analysis of necrotic areas or non-neoplastic tissues 
encountered in cores. Results of the analysis were mea-
sured and calculated by the software and were presented 
in three forms: a) mean percentage of all positive cells, b) 
percentage of cells with different expression of proteins [+3 
(highly positive), +2 (medium positive), +1 (low positive) 
and 0 (negative)] and c) H-score, which was calculated with 
following formula: H-score = (% of +3-positive cells × 3) 
+ (% of +2-positive cells × 2) + (% of +1-positive cells).
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Statistical analysis. Data distribution was tested with 
Shapiro-Wilks test. Some data showed non-Gaussian 
distribution thus Kruskal-Wallis test was used for finding 
differences between more than two groups and subsequently 
U-Mann-Whitney test for differences between two groups. 
All analyses were performed with STATISTICA for Win-
dows 13.1 (StatSoft, Kraków, Poland).
Results
The mean age of patients with testicular tumors 
analyzed was 35.5 ± 12.3 years (mean ± SD) while 
mean tumor size was 35.5 ± 19.1 mm. Detailed data 
is presented in Table 1.
Patients with seminomas were older than patients 
with non-seminomas but the difference did not reach 
statistical significance (p = 0.07). When compared be-
tween separate groups of non-seminomas, patients with 
embryonal carcinoma component were significantly 
younger than patients with seminoma (p = 0.008) 
and patients with yolk sac tumor component (p = 0.03). 
There were no age differences between patients with 
yolk sac tumor component and patients with semi-
noma (p = 0.86). Tumor size showed no statistically 
significant differences between any groups studied. 
Mean number of nuclei measured in each case was 
4941 ± 1874 (mean ± SD).
Nucleolin expression and subpopulation of NCL-
-positive cells in seminomas and non-seminomas
We analyzed the percentage of NCL-positive cells, 
percentages of subgroups of highly positive (+3), 
medium positive (+2), low positive (+1) and neg-
ative cells (0) as well as H-score in seminomas and 
non-seminomas. Seminomas showed higher expres-
sion of NCL indicated by higher H-score and higher 
percentage of positive cells than non-seminomas 
(p = 0.0009 and p = 0.024, respectively). Interesting 
results were found in subpopulations of NCL-pos-
itive cells. The percentage of +3-positive cells was 
higher (p = 0.0004) while percentages of +2, +1 
and negative cells were lower in seminomas than in 
non-seminomas (p = 0.001, p = 0.002 and p = 0.025, 
respectively) (Table 2). Differences in percentages of 
subgroups of NCL-positive cells indicate the hetero-
geneity of expression of nucleolin between seminomas 
and non-seminomas.
Nucleolin expression and subpopulation  
of NCL-positive cells in seminomas vs embryonal 
carcinoma- and yolk sac tumor-component  
of non-seminomas
We compared NCL expression between seminomas and 
two subtypes of non-seminomatous tumors — embry-
onal carcinomas and yolk sac tumors separately. Both 
Figure 1. Nucleolin (NCL) expression in seminoma, embryonal carcinoma and yolk sac tumor. 1–3 hematoxylin and eosin 
staining; 1 — seminoma, 2 — embryonal carcinoma, 3 — yolk sac tumor. Microphotographs 1a–3a present NCL immunore-
activity, whereas figures 1b–3b present analyses of the NCL immunoreactivity by Aperio Scan Scope software in respective 
tumors. Sections were stained by immunohistochemistry as described in Materials and Methods. 
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embryonal carcinomas and yolk sac tumors showed 
lower expression of NCL than seminomas indicated by 
H-score (p = 0.0016 and p = 0.02, respectively).
The percentage of NCL-positive cells in embryo-
nal carcinomas did not differ from the percentage of 
NCL-positive in seminomas while there were signifi-
cant differences in subpopulations of cells. We found 
lower population of +3-positive cells (p = 0.0002) and 
higher populations of +2-positive and +1-positive 
cells in embryonal carcinomas than in seminomas 
(p = 0.0005 and p = 0.003, respectively) (Table 3).
The percentage of NCL-positive cells in yolk sac 
tumors was lower than in seminomas (p = 0.015). The 
differences in subpopulation of cells in yolks sac tum-
ors were slightly different than in embryonal carcino-
mas. We found lower population of +3-positive cells 
(p = 0.049) and higher populations of +1-positive 
cells (p = 0.045) and negative cells (p = 0.01) in yolk 
sac tumors than in seminomas but we found no dif-
ferences in +2-positive cell subpopulation (Table 3). 
The results show different heterogeneity of sub-
populations of NCL-positive cells in embryonal carci-
nomas and yolk sac tumors compared to seminomas.
The analysis of NCL expression in embryonal 
carcinomas and yolk sac tumors showed no significant 
differences between these two tumor types either in 
H-score value or in percentages of respective groups 
of NCL-positive and negative cells (Table 3).
Table 1. Patients’ age and tumor size
Seminomas Non-seminomas Embryonal carcinomas Yolk sac tumors
Age (years) 038.6 ± 12.0a 32.4 ± 10.4 28.6 ± 7.00 039.3 ± 12.2b
Tumor size [mm] 36.7 ± 25.4 34.8 ± 14.3 31.7 ± 11.5 44.0 ± 19.2
The results present mean ± SD. Letters by superscripts indicate significant differences between groups: ap = 0.008, seminomas vs. embryonal carci-
nomas; bp = 0.03, yolk sac tumors vs. embryonal carcinomas.
Table 2. Semiquantitative analysis of the immunohistochemical expression of nucleolin in seminomas and non-seminomas 
of the testis
Immunoreactivity Seminomas Non-seminomas p
% of positive nuclei 97.71 ± 1.60 95.88 ± 3.800 0.024
% of +3 positive nuclei 81.41 ± 7.67 68.87 ± 12.94 0.0004
% of +2 positive nuclei 13.29 ± 5.10 21.41 ± 8.80 0.001
% of +1 positive nuclei 03.01 ± 1.67 05.56 ± 3.28 0.002
% of negative nuclei 02.27 ± 1.60 04.11 ± 3.81 0.025
H-score 273.81 ± 11.94 255.03 ± 20.74 0.0009
The results present mean ± SD. +3, +2 and +1 denote highly, medium, and low positive immunoreactivity, respectively. H-score was calculated as 
described in Material and Methods.
Table 3. Semiquantitative analysis of the immunohistochemical expression of nucleolin in seminomas, embryonal carcinomas 
and yolk sac tumors of the testis
Immunoreactivity Seminomas Embryonal  
Carcinomas
Yolk Sac Tumors
% of positive nuclei 97.71 ± 1.6a00 95.97 ± 4.450 95.70 ± 2.240
% of +3 positive nuclei 81.41 ± 7.67b, c 68.80 ± 11.59 69.00 ± 15.83
% of +2 positive nuclei 13.29 ± 5.10d0 21.80 ± 7.440 20.72 ± 11.35
% of +1 positive nuclei 03.01 ± 1.67e, f 5.34 ± 3.00 5.98 ± 3.87
% of negative nuclei 2.27 ± 1.60g 4.02 ± 4.46 4.30 ± 2.23
H-score 273.81 ± 11.94h, i 255.35 ± 20.720 254.42 ± 21.790
Table legend as for Table 2. Letters in superscripts indicate significant differences between groups: ap = 0.015 seminomas vs yolk sac tumors; 
b, cp = 0.0002 and p = 0.049, seminomas vs. embryonal carcinomas and seminomas vs. yolk sac tumors, respectively; dp = 0.0005 seminomas vs. 
embryonal carcinomas; e, fp = 0.003 and p = 0.045, seminomas vs embryonal carcinomas and seminomas vs. yolk sac tumors, respectively; gp = 0.01 
seminomas vs yolk sac tumors; h, ip = 0.0016 and p = 0.02, seminomas vs. embryonal carcinomas and seminomas vs. yolk sac tumors, respectively.
143Nucleolin and nucleophosmin in testicular tumors
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2019
10.5603/FHC.a2019.0015
www.fhc.viamedica.pl
Nucleophosmin expression and subpopulation  
of NPM-positive cells in seminomas  
and non-seminomas
We also analyzed the percentage of NPM-positive 
cells, percentages of subgroups of highly positive 
(+3), medium positive (+2), low positive (+1) and 
negative cells (0) as well as H-score in seminomas and 
non-seminomas. We found no significant differenc-
es in any analyzed parameters for NPM expression 
between seminomas and non-seminomatous group 
(Table 4). The expression of NPM did not differ 
between embryonal carcinomas and yolk sac tumors 
(data not shown). 
Discussion
In the current study, we analyzed nuclear expression 
of two proteins — nucleolin and nucleophosmin in 
seminomas and non-seminomas by standard IHC 
technique performed on tissue microarrays. Only 
NCL showed differences of expression between 
these tumor types. Nuclear expression of NCL was 
significantly higher in seminomas than in embryonal 
carcinomas and yolk sac tumors, while there were no 
statistically significant differences between the latter 
ones. We found no differences in NPM expression 
between tumor types studied. There were no previous 
studies on these two proteins in testicular pathology 
including germ cell tumors.
NCL and NPM are among most abundant nu-
cleolar proteins forming argyrophilic nucleolar 
organizer regions (AgNOR) that were extensively 
studied since eighties in different pathologies but only 
few publications on AgNOR in testicular pathology 
can be found. Meng et al. analyzed area of AgNOR 
in testicular carcinoma in situ (CIS) finding higher 
level of AgNOR in CIS associated with non-semi-
nomas than with seminomas. They also mentioned 
that mean area of AgNOR in solid tumor cells did 
not differ between seminomas and non-seminomas 
but they pointed to difficulties in objective assessing 
the parameters studied [18]. Ohyama et al. studied 
forty-five patients with invasive testicular tumors and 
they found higher number of AgNOR per nucleus in 
seminomas than in non-seminomas [19]. Results of 
the study by Ohyama et al. are in concordance with 
the results of our current study. It may be stated that 
higher AgNOR parameters in seminomas are related 
to higher NCL expression since it is one of the main 
AgNOR-related proteins [11, 14].
The expression of NCL in different histologic types 
of cancer was previously studied in limited series of 
tumor types. The results of our previous study on 
a group of 87 ductal and 11 lobular invasive breast 
cancers showed higher expression of NCL in nucle-
olus and in karyoplasm in ductal than lobular breast 
cancers [17]. Xu et al. showed higher expression of 
nucleolin in squamous cell lung cancers than in pul-
monary adenocarcinomas but their results were not 
statistically significant [20].
At the molecular level seminomas differ from 
non-seminomas by many markers and pathways 
including proteins, miRNA, mRNA and DNA meth-
ylation [21]. Seminomas molecular characteristic 
mirrors early germ cells while embryonal carcinoma 
resembles embryonic stem cells [8]. Among markers 
of pluripotency, Sox2 is the one that is expressed in 
non-seminomas with no expression in seminomas 
[9, 10]. Experiments on glioblastoma stem-like cells 
showed that increased NCL expression downregu-
lated Sox2. NCL decreased stem-like characteristics 
of Sox2 expression and the inhibitory effect of NCL 
was due to the transcription inhibition and also was 
observed on protein level. NCL knockout increased 
the expression of Sox2. Lower expression of NCL was 
accompanied by the upregulation of glioblastoma 
stem cell (GSC) markers including Sox2 [22]. The 
higher nucleolin expression in Sox2- negative semi-
nomas may suggest similar molecular pathway to the 
one described in glioblastoma stem-like cells.
Nuclolin is a protein interacting with human 
telomerase reverse transcriptase (hTERT) and this 
Table 4. Parameters of immunohistochemical expression of NPM in germ cell testicular tumors
Immunoreactivity Seminomas Non-seminomas p 
% of positive nuclei 89.89 ± 7.620 83.03 ± 17.29 0.32
% of +3 positive nuclei 42.87 ± 22.00 36.19 ± 23.85 0.35
% of +2 positive nuclei 30.33 ± 7.430 30.15 ± 10.33 0.94
% of +1 positive nuclei 16.19 ± 10.17 16.71 ± 9.420 0.75
% of negative nuclei 10.60 ± 7.230 16.97 ± 17.29 0.45
H-score 205.48 ± 45.820 185.56 ± 63.220 0.35
Table legend as for Table 2.
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interaction is necessary for nucleolar localization of 
hTERT and its activity [23]. NCL overexpression caus-
es nucleolar localization of telomerase in cancer cells 
[24]. Schrader et al. found high expression and high 
activity of hTERT in both seminomas and embryonal 
carcinomas (with high range of results) but lower in 
yolk sac tumors; however the differences between all 
groups studied were not statistically significant [25]. 
Turnbull et al. found some variants of SNPs in hTERT 
gene independently associated with testicular germ 
cell tumors, one of them showing stronger association 
with seminomas than with non-seminomas [26]. The 
differences in NCL expression between seminomas 
and non-seminomas found in our study may suggest 
the possible different interactions of nucleolin with 
hTERT in testicular tumors that might be modified 
by single nucleotide polymorphism in hTERT gene. 
We did not find any differences in nucleophosmin 
expression between seminomas and non-seminomas. 
Published results on NPM expression in different his-
tologic tumor types including malignant and benign 
ones are ambiguous. Pianta et al. studied 46 thyroid 
tumors (10 benign and 33 malignant) and they found 
higher NPM expression in papillary cancers than in 
follicular or undifferentiated cancers. On the other 
hand, NPM expression in benign follicular adeno-
mas was higher than in follicular or undifferentiated 
carcinomas [27]. Sari et al. studied NPM expression 
in 68 renal tumors (9 benign and 59 malignant) and 
found nuclear NPM expression in chromophobe, 
papillary and clear cell cancers with no expression in 
benign oncocytomas and highly aggressive sarcoma-
toid cancers. They also found higher nucleolar NPM 
expression in benign oncocytomas and in highly ag-
gressive sarcomatoid renal cell cancers than in clear 
cell or papillary renal cell cancers [28]. These results 
may suggest that NPM expression is neither related 
to benign vs malignant tumors nor to low vs. high 
malignant cancers. Relatively high standard deviation 
of NPM expression found in current study indicates 
high heterogeneity of NPM expression in all tumor 
types. Further studies are required for assessing the 
role of NPM in solid tumor pathology.
In this study, the expression of NCL and NPM in 
seminomas and non-seminomas as well as different 
subpopulations of cells expressing both proteins 
were analyzed for the first time. The differences in 
subpopulations of cells expressing NCL between semi-
nomas and non-seminomas indicate new aspect of the 
biology of these tumors. However, our results should 
be considered as initial observations that require 
further studies including correlations with clinical 
data, also prospective ones, for the studied patients 
(e.g. disease-free survival). Moreover, the number of 
yolk sac tumors cases should be increased for clinical 
studies. Overall, our results show differences in the 
expression of selected nucleolar protein in testicular 
tumors that require further studies. 
Acknowledgements
Authors are thankful to Ms. Władysława Surma for 
technical assistance in scanning slides with ScanScope 
(Aperio Technologies Inc.).
Conflict of interest
Authors declare no conflict of interest.
References
1. Bray F, Richiardi L, Ekbom A, et al. Trends in testicular can-
cer incidence and mortality in 22 European countries: con-
tinuing increases in incidence and declines in mortality. Int 
J Cancer. 2006; 118(12): 3099–3111, doi: 10.1002/ijc.21747, 
indexed in Pubmed: 16395710.
2. Elzinga-Tinke JE, Dohle GR, Looijenga LHj. Etiology and 
early pathogenesis of malignant testicular germ cell tumors: 
towards possibilities for preinvasive diagnosis. Asian J An-
drol. 2015; 17(3): 381–393, doi: 10.4103/1008-682X.148079, 
indexed in Pubmed: 25791729.
3. Young RH. Testicular tumors--some new and a few peren-
nial problems. Arch Pathol Lab Med. 2008; 132(4): 548–564, 
doi: 10.1043/1543-2165(2008)132[548:TTNAAF]2.0.CO;2, 
indexed in Pubmed: 18384207.
4. Ulbright TM. Germ cell tumors of the gonads: a selective 
review emphasizing problems in differential diagnosis, newly 
appreciated, and controversial issues. Mod Pathol. 2005; 18 
Suppl 2: S61–S79, doi: 10.1038/modpathol.3800310, indexed 
in Pubmed: 15761467.
5. Looijenga LHJ, Stoop H, de Leeuw HP, et al. POU5F1 
(OCT3/4) identifies cells with pluripotent potential in hu-
man germ cell tumors. Cancer Res. 2003; 63(9): 2244–2250, 
indexed in Pubmed: 12727846.
6. Mitchell RT, Camacho-Moll M, Macdonald J, et al. Intra-
tubular germ cell neoplasia of the human testis: heteroge-
neous protein expression and relation to invasive potential. 
Mod Pathol. 2014; 27(9): 1255–1266, doi: 10.1038/mod-
pathol.2013.246, indexed in Pubmed: 24457464.
7. Moch H., Humphrey PA, Ulbright TM, Reuter VE (ed.). 
(2016). WHO Classification of Tumours of the Urinary Sys-
tem and Male Genital Organs. 4th Edition. International 
Agency for Research on Cancer, Lyon, pp 190-193.
8. Honecker F, Stoop H, Mayer F, et al. Germ cell lineage differ-
entiation in non-seminomatous germ cell tumours. J Pathol. 
2006; 208(3): 395–400, doi: 10.1002/path.1872, indexed in 
Pubmed: 16273510.
9. de Jong J, Stoop H, Gillis AJM, et al. Differential expression 
of SOX17 and SOX2 in germ cells and stem cells has biological 
and clinical implications. J Pathol. 2008; 215(1): 21–30, doi: 
10.1002/path.2332, indexed in Pubmed: 18348160.
10. Looijenga LHJ. Human testicular (non)seminomatous germ 
cell tumours: the clinical implications of recent pathobiologi-
cal insights. J Pathol. 2009; 218(2): 146–162, doi: 10.1002/ 
/path.2522, indexed in Pubmed: 19253916.
11. Ma N, Matsunaga S, Takata H, et al. Nucleolin functions in 
nucleolus formation and chromosome congression. J Cell Sci. 
145Nucleolin and nucleophosmin in testicular tumors
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2019
10.5603/FHC.a2019.0015
www.fhc.viamedica.pl
2007; 120(Pt 12): 2091–2105, doi: 10.1242/jcs.008771, indexed 
in Pubmed: 17535846.
12. Abdelmohsen K, Gorospe M. RNA-binding protein nucleo-
lin in disease. RNA Biol. 2012; 9(6): 799–808, doi: 10.4161/ 
/rna.19718, indexed in Pubmed: 22617883.
13. Tajrishi MM, Tuteja R, Tuteja N. Nucleolin: The most abun-
dant multifunctional phosphoprotein of nucleolus. Commun 
Integr Biol. 2011; 4(3): 267–275, doi: 10.4161/cib.4.3.14884, 
indexed in Pubmed: 21980556.
14. Masiuk M, Urasinska E, Domagala W. Simultaneous 
measurement of nucleolin and estrogen receptor in breast 
cancer cells by laser scanning cytometry. Anticancer Res. 
2004;24:963-966. Indexed in Pubmed. ; 15161050.
15. Šašinková M, Holoubek A, Otevřelová P, et al. AML-associa-
ted mutation of nucleophosmin compromises its interaction 
with nucleolin. Int J Biochem Cell Biol. 2018; 103: 65–73, doi: 
10.1016/j.biocel.2018.08.008, indexed in Pubmed: 30130654.
16. Chen S, He H, Wang Y, et al. Poor prognosis of nucleophos-
min overexpression in solid tumors: a meta-analysis. BMC 
Cancer. 2018; 18(1): 838, doi: 10.1186/s12885-018-4718-6, 
indexed in Pubmed: 30126359.
17. Masiuk M. Expression and intranuclear distribution of nucle-
olin in estrogen receptor-negative and estrogen receptor-pos-
itive breast cancers in women measured by laser scanning 
cytometry]. Ann Acad Med Stetin. 2006;52:23-32. In Polish. 
Indexed in Pubmed. ; 17633394.
18. Meng FJ, Giwercman A, Skakkebaek NE. Investigation of car-
cinoma in situ cells of testis by quantification of argyrophilic 
nucleolar organizer region associated proteins (AgNORs). 
J Pathol. 1996; 180(2): 206–213, doi: 10.1002/(SICI)1096-
9896(199610)180:2<206::AID-PATH640>3.0.CO;2-Y, in-
dexed in Pubmed: 8976882.
19. Ohyama C, Ito A, Tokuyama S, et al. [Clinical significance of 
proliferating cell nuclear antigen (PCNA) and argyrophilic 
nucleolar organizer region (AgNOR) in testicular tumors]. Ni-
hon Hinyokika Gakkai Zasshi. 1995; 86(10): 1543–1551, doi: 
10.5980/jpnjurol1989.86.1543, indexed in Pubmed: 7474604.
20. Xu JY, Lu S, Xu XY, et al. Prognostic significance of nuclear 
or cytoplasmic nucleolin expression in human non-small cell 
lung cancer and its relationship with DNA-PKcs. Tumour 
Biol. 2016; 37(8): 10349–10356, doi: 10.1007/s13277-016-4920-
6, indexed in Pubmed: 26846099.
21. Shen H, Shih J, Hollern DP, et al. Cancer Genome Atlas 
Research Network. Integrated Molecular Characterization 
of Testicular Germ Cell Tumors. Cell Rep. 2018; 23(11): 
3392–3406, doi: 10.1016/j.celrep.2018.05.039, indexed in Pu-
bmed: 29898407.
22. Ko CY, Lin CH, Chuang JY, et al. MDM2 Degrades 
Deacetylated Nucleolin Through Ubiquitination to Promote 
Glioma Stem-Like Cell Enrichment for Chemotherapeutic 
Resistance. Mol Neurobiol. 2018; 55(4): 3211–3223, doi: 
10.1007/s12035-017-0569-4, indexed in Pubmed: 28478507.
23. Wu YL, Dudognon C, Nguyen E, et al. Immunodetection 
of human telomerase reverse-transcriptase (hTERT) re-ap-
praised: nucleolin and telomerase cross paths. J Cell Sci. 
2006; 119(Pt 13): 2797–2806, doi: 10.1242/jcs.03001, indexed 
in Pubmed: 16772337.
24. Khurts S, Masutomi K, Delgermaa L, et al. Nucleolin interacts 
with telomerase. J Biol Chem. 2004; 279(49): 51508–51515, 
doi: 10.1074/jbc.M407643200, indexed in Pubmed: 15371412.
25. Schrader M, Burger A, Müller M, et al. The differentiation 
status of primary gonadal germ cell tumors correlates inversely 
with telomerase activity and the expression level of the gene 
encoding the catalytic subunit of telomerase. BMC Cancer. 
2002; 2(1), doi: 10.1186/1471-2407-2-32.
26. Turnbull C, Rapley EA, Seal S, et al. UK Testicular Cancer 
Collaboration. Variants near DMRT1, TERT and ATF7IP 
are associated with testicular germ cell cancer. Nat Genet. 
2010; 42(7): 604–607, doi: 10.1038/ng.607, indexed in Pu-
bmed: 20543847.
27. Pianta A, Puppin C, Franzoni A, et al. Nucleophosmin is 
overexpressed in thyroid tumors. Biochem Biophys Res Com-
mun. 2010; 397(3): 499–504, doi: 10.1016/j.bbrc.2010.05.142, 
indexed in Pubmed: 20515654.
28. Sari A, Calli A, Altinboga AA, et al. Nucleophosmin expres-
sion in renal cell carcinoma and oncocytoma. APMIS. 2012; 
120(3): 187–194, doi: 10.1111/j.1600-0463.2011.02835.x, in-
dexed in Pubmed: 22339675.
Submitted: 2 April, 2019 
Accepted after reviews: 3 September, 2019 
Available as AoP: 12 September, 2019
